

Review Article

Bone cancer pain and the role of RANKL/OPG

D.R. Clohisy and P.W. Mantyh

Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, USA

Abstract

Cancer-induced bone diseases are common and can have a devastating impact at the end of life. One of the most difficult sequelae of cancer is metastases to the skeleton, an event that results in bone destruction and bone cancer pain. Bone cancer pain is usually progressive as the disease advances, and is particularly difficult to treat. Recently, experimental models of bone cancer pain have been developed and have provided seminal insight in understanding the pathophysiology of bone cancer pain. Animal models of bone cancer provided the finding that bone destruction (osteolysis) is associated with pain, and it has been determined that cancer-induced osteolysis is mediated by osteoclasts. Having established that RANK ligand contributed to cancer-induced osteoclastogenesis, it was determined that disruption of the RANKL-RANK axis with OPG inhibited tumor-induced osteoclastogenesis and decreased bone cancer pain.

Keywords: Bone Cancer, Pain, Osteoprotegerin, Osteolysis

Skeletal involvement with cancer can include malignancies that originate within bone or malignancies that metastasize from a primary site of cancer to the bone. Malignancies originating in bone are less common and include multiple myeloma, primary lymphoma of bone, and bone sarcomas. Metastatic bone cancer is more common than primary bone cancer and occurs with high incidence in patients with primary cancers of the prostate, breast, or lung. In the United States, there are hundreds of thousands of patients diagnosed with development of, or progression of, metastatic bone cancer annually. When combined with the number of patients already living with metastatic bone cancer, it becomes clear that the incidence of bone cancer is significant.

Unfortunately, the development of or progression of skeletal cancer is almost certainly a harbinger of future problems. These problems are defined by the complications that develop as skeletal cancers progress, and include bone cancer pain, skeletal fracture, hypercalcemia, and the need for palliative radiation therapy and/or surgical stabilization of bones incapable of maintaining their mechanical integrity. The most common problem among these is bone cancer pain.

Bone cancer pain can be the first symptom of metastatic cancer or, more commonly, a symptom of advanced cancer. Bone cancer pain symptoms dominate quality of life, as patients with advanced cancers cope with their final years and months. Unfortunately, the vast majority of patients with bone cancer cannot be cured of their disease, and as a result, treatment modalities and decisions focus on palliation of cancer symptoms.

Bone cancer pain is the most common form of cancer-associated pain. This type of pain is often under-treated or not responsive to available therapies. The onset and progression of bone cancer pain is often insidious. Treatments initially focus on prescription of anti-inflammatory agents and the use of osteoclast-inhibiting agents. As patients survive, bone cancer pain is frequently no longer responsive to these simple measures. Narcotics and external beam radiation are then recommended. This more intense level of treatment is usually effective initially, but if patients survive additional months or years, the pain often recurs and intensifies. Modalities used to treat this higher level of pain are limited, and their morbidities are significant. Remaining options include significant escalation of pharmaceuticals, radiation, and/or surgical treatment of painful or mechanically incompetent bones. Morbidities for these treatments are high. Treatment with escalation of significant doses of narcotics can be complicated by the life-disrupting problems of constipation, confusion, lethargy, and risk of falling. Radiation can cause local skin irritation, myelosuppression, and nerve injury. Surgery in medically impaired cancer patients has significant risks, including problems with blood loss, wound healing, failure of surgical reconstruction, and even perioperative death¹.

Dr Clohisy has a grant from Amgen. Dr Mantyh has no conflict of interest.

Corresponding author: Denis R. Clohisy, MD, Dept. of Orthopaedic Surgery, University of Minnesota, 420 Delaware Street SE, MMC 806, Minneapolis, MN 55455, USA
E-mail: clohi001@umn.edu

Accepted 4 May 2004




Figure 1. Cellular mechanism of tumor-induced osteolysis. Osteolytic cancers induce osteoclast-mediated osteolysis by producing factors that multiply osteoclast precursor cells and increase expression RANKL, resulting in an increase in the number and activity of osteoclasts.

The tragic plight of cancer patients with the potential to survive months or years while battling bone cancer pain can be attributed to two clear failures in health professionals' attempts to provide palliative care. The first failure is a paucity of treatments capable of halting the progression of bone cancers. The second is the absence of pain therapies that have a known mechanistic basis of action. Obviously, enormous resources have targeted improving this first point of failure. For decades, investigations regarding mechanism of cancer spread, invasion and growth have been commonplace. In contrast, until recently there has been very little basic laboratory investigation focused on understanding the mechanisms of development and maintenance of bone cancer pain.

Experimental model of bone cancer pain

Recent work has provided experimental models of bone cancer pain in mice and rats²⁻⁵. In one murine model, cancer cells (termed 2472 sarcoma cells) are injected directly into mouse femora. In this experimental model, bone cancers grow at the site of injection, destroy bone, and increase osteoclast number^{4,6}. As tumors progress, animals manifest behavioral and neurochemical characteristics of bone cancer pain⁴.

Initial investigation with this experimental model focused on defining the cellular means through which cancers caused osteolysis. Findings indicated that tumors increase the number and size of osteoclasts at sites of tumor⁶, showed that

osteoclasts were required for cancer-induced bone destruction⁷, determined that osteoclast number increased because of accelerated osteoclastogenesis, and determined that the precursor cells that formed osteoclasts at sites of tumor were post-mitotic osteoclast precursor cells (Figure 1).

Having defined an essential and pathologic role for osteoclastogenesis in this model, the molecular features of 2472 tumor-induced osteoclastogenesis were determined. Findings revealed that molecules critical for osteoclastogenesis were involved. Most notably, analysis of sites of bone cancer by *in situ* hybridization showed an increase in expression of RANK and RANKL⁸ (Figure 1). In addition, it has recently been shown that tumor-secreted PGE2 may account for a portion of the cancer-induced osteoclastogenesis and osteolysis⁹.

Tumor progression and osteoclastogenesis in this direct bone injection model rapidly accelerate between 7 and 10 days after intraosseous cancer cell injection⁶. Accelerated tumor growth continues until 21 days after injection. Study of animals' behavior revealed that tumor-bearing mice exhibited behavioral changes exemplified by ongoing pain, activity-induced pain, and pain following non-painful limb stimulation (allodynia). The presence of these pain behaviors was supported by characterization of neural composition and neurochemistry of the peripheral and central nervous system.

When animals had bone cancer pain, no obvious alteration in innervation of bone or periosteum was appreciated⁴, and there was no impact on the percentage of small diameter DRG neurons that expressed substance P (31%) or IB4-




Figure 2. Neurochemical changes in the dorsal horn of the spinal cord 21 d after unilateral injection of an osteolytic sarcoma in the intramedullary space of the femur. Confocal images of coronal sections of the L4 spinal cord illustrate the distribution of DYN with arrows indicating the cell bodies expressing this pro-hyperalgesic peptide.

expressing neurons (73%). In contrast, composition of the spinal cord was altered in mice with bone cancer pain. Specifically, spinal cords from these animals had three dramatic changes: astrocyte hypertrophy without neuronal loss, expression of the prohyperanalgesic peptide dynorphin, and increased expression of *c-fos* in the dorsal horn and deep within the spinal cord (Figure 2). To evaluate for pain after non-painful limb stimulation, dorsal root ganglia (DRGs) were studied immediately following gentle manipulation of cancerous limbs. This prompted robust internalization of substance P and dramatic increase in lamina I neuron expression of *c-fos*, a finding that was specific to bone-residing and not soft tissue cancers.

When compared to neurochemical findings characteristic of inflammatory or neuropathic pain, the neurochemical features of bone cancer pain are unique¹⁰. For example, in neuropathic pain, astrocyte hypertrophy occurs in combination with neuronal loss and decreased substance P levels. In contrast, bone cancer pain model exhibited astrocyte hypertrophy without neuronal loss and no change in substance P levels. Inflammatory pain states are characterized by increased substance P, calcitonin gene-related peptide and substance P in the spinal cord. Bone cancer pain did not exhibit any of these changes.

OPG treatment reduces bone cancer pain

Based on behavioral and neurochemical data, it was appreciated that progressive abnormalities in spinal cord neurochemistry correlated with the extent of bone destruction⁴. This observation generated the hypothesis that cancer-induced osteolysis caused bone cancer pain. As molecular characterization of the bone cancer microenvironment revealed that sites of painful, osteolytic bone cancers had increased levels of RANK and RANKL (Figure 1), the possibility was raised that disruption of the RANK-RANKL axis




Figure 3. OPG abolishes sarcoma-induced bone destruction. High-resolution radiographs of sham-injected (*a* and *c*) and sarcoma-injected (*b* and *d*) femora from mice that received vehicle (*a* and *b*) or OPG (*c* and *d*). At 17 days after sarcoma injection, there is substantial bone destruction in the distal femur without OPG (*b*; bone destruction score of 4; white arrowhead), whereas there is no bone destruction in the sarcoma-injected mouse that received OPG (*d*; bone destruction score of 0). The amalgam plug (*a*, black arrow) prevents extraosseous growth of the tumor. Scale bars represent 10 mm.

via OPG treatment may reduce cancer-induced, osteoclast-mediated osteolysis and pain^{11,12}.

To determine if disruption of the RANK-RANKL interaction influenced cancer-induced osteolysis and bone cancer




Figure 4. OPG reduces the number of osteoclasts and bone destruction in mice injected with sarcoma cells. Femur section stained with hematoxylin and eosin (*a* and *c*), showing tumor cells (arrowheads) and mineralized bone (arrows), or stained with tartrate-resistant acid phosphatase (*b* and *d*), showing osteoclasts (dark violet) in sarcoma-injected mice that received vehicle (*a* and *b*) or OPG (*c* and *d*) and prevents the bone destruction seen in vehicle-treated mice (arrows, *a* and *c*). In addition, treatment with OPG does not modify tumor growth, as there are tumor cells in both sarcoma-injected, vehicle-treated mice and sarcoma-injected, OPG-treated mice (arrowheads, *a* and *c*). Scale bar represents 500 μm .

pain, mice were treated with OPG (OPG-Fc) while still in the early stages of bone cancer development. Treatment with OPG early in the development of bone cancer decreased tumor osteolysis. Bone destruction was significantly less in OPG-treated mice compared to vehicle-treated mice (Figure 3), with the majority of femora from OPG-treated mice showing no evidence of cancer-induced osteolysis¹³. Histologic evaluation of vehicle- and OPG-treated mice demonstrated no significant reduction in tumor burden, but a dramatic reduction in osteoclast number (Figure 4). These findings indicated that the RANK-RANKL axis was pathogenic in the development of 2472 cancer-induced osteolysis.

Treatment with OPG early in the development of bone cancer also decreased bone cancer pain. Based on evaluation of pain behaviors, treatment with OPG provided significant

reduction in pain, as manifested by a 73% reduction in activity-related guarding, a 44% decrease in the number of flinches, and a 30% decrease in palpation-induced pain behaviors. Improvements in pain behaviors were accompanied by normalization of several of the neurochemical characteristics of bone cancer pain (Figure 5). Specifically, there was a reduction in astrocyte hypertrophy, decreased spinal cord expression of c-fos and an absence of spinal cord dynorphin. In addition, following non-painful palpation of cancerous limbs, there was significant reduction in substance P receptor internalization and c-fos expression in laminae I of the spinal cord.

When mice with advanced bone cancer pain were treated with OPG, an impressive reduction in pain was also realized (Figure 7). Twelve days after intraosseous injection of 2472




Figure 5. OPG blocks both spontaneous and evoked pain behaviors seen in sarcoma-injected mice. Data include limb use score (0-4) during ambulation in an open field (*a*), the number of spontaneous flinching behaviors in a 2-minute observation period (*b*), nocifensive behavior score obtained during a normally non-noxious palpation (*c*), and the number of flinching behaviors in a 2-minute observation period after the completion of a normally non-noxious palpation (*d*) 17 days after sham or sarcoma injection into the femora of mice that subsequently received vehicle or OPG. Daily treatment with OPG significantly reduces spontaneous and evoked nociceptive behaviors or behaviors indicative of pain. Data represent mean \pm SEM. Dashed lines, baseline values. *, $P < 0.05$; **, $P < 0.01$; and ***, $P < 0.001$; one-way ANOVA and Fisher's PLSD (brackets and downward arrows indicate groups being compared).

cells, mice had significant osteolysis and significant pain. Treatment of these animals with OPG halted cancer-induced bone destruction, stabilized behavioral measures of pain, and prompted corrective neurochemical reorganization of the spinal cord¹⁴. Bone destruction ceased after treat-

ment with OPG, as the extent of destruction nine days after treatment (day 21) with OPG was equivalent to the extent of bone destruction noted when OPG treatment began (day 12). Vehicle-treated animals experienced progressive bone destruction through the duration of the experiment.




Figure 6. Line graph showing that OPG treatment reduces movement-evoked pain-related behaviors in sarcoma-injected animals. Activity-related guarding in sham and sarcoma-injected animals that received either vehicle or OPG from day 12-21 (OPG, 5mg/kg/day, s.c.). OPG treatment stabilized activity-related guarding in sarcoma-injected animals. Values represent the mean \pm SEM. #, $P < 0.05$ as compared with sarcoma-injected vehicle-treated animals (one-way ANOVA, Fisher's PLSD).

Measures of ongoing pain behaviors and activity-related pain behaviors demonstrated the presence of significant pain 12 days after tumor cell injection. These abnormalities stabilized following OPG treatment but progressed following vehicle treatment.

Several neurochemical measures of pain that were abnormal 12 days after tumor cell inoculation improved following OPG treatment, but not vehicle treatment. These measures included reduced spinal cord expression of c-fos, reduced spinal cord expression of dynorphin, and reduced spinal cord astrocyte hypertrophy¹⁴. In addition, OPG treatment reduced cancer-induced sensitization of primary afferent neurons observed after non-painful palpation of cancerous limbs. Following non-painful palpation, OPG-treated mice had reduced pain behaviors, attenuated c-fos expression in laminae I-II, and no substance P internalization in the spinal cord following non-painful palpation, when compared to vehicle-treated animals (Figure 6).

Taken in total, these findings revealed that OPG treatment had profound corrective influences on bone cancer pain behaviors, on neurochemical alterations of the spinal cord, and on cancer-induced osteolysis.

Potential mechanisms of OPG action on pain.

Since this initial demonstration that osteolysis is linked to bone cancer pain, additional reports have confirmed that a reduction in cancer-induced osteolysis decreases bone cancer pain^{9,15,16}. It therefore seems that one mechanism through which OPG treatment reduces pain is via its known effect on osteoclast formation, survival, and activity. It is unclear, however, how osteoclastic bone resorption causes pain. Several possibilities should be considered. First, osteoclasts themselves may be responsible for nociceptive stimulation, which could reflect osteoclast-mediated direct injury




Figure 7. Histogram showing that ongoing osteoclast activity is involved in the sensitization of primary afferent neurons in advanced bone cancer pain. Results are expressed as the mean number of c-Fos-expressing laminae I-II neurons (A) and the number of SPR-IR endosomes in laminae I SPR-IR neurons (B) after normally non-noxious palpation in sham and sarcoma-injected animals before OPG treatment and after OPG or vehicle treatment. Note that OPG treatment from day 12-21 abolishes spinal laminae I-II c-Fos expression and SPR internalization induced by a normally non-noxious palpation at day 21 in sarcoma-injected mice. One-way ANOVA, Fisher's PLSD: *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ [as compared with respective sham animals (brackets and downward arrows indicate the groups being compared)].

to nociceptive neurons within bone or, alternatively, could reflect exposure of acid-sensing neuronal channels to the acidic pH of the osteoclast resorption bay. A second possibility is that osteoclasts themselves do not cause pain, but rather osteoclast-mediated bone loss decreases the mechanical integrity of the cancer-ridden bone, resulting in mechanical nociceptor stimulation.

Acknowledgements

This work was supported by a Merit Review from the Veterans Administration, National Institutes of Health Grants NS23970, AG11852, CA11986, AR47302, AR43595, CA90434, and the Roby C Thompson Jr Endowment in Musculoskeletal Oncology Minnesota Legislative Initiative Fund.

References

1. Clohisy DR, Le CT, Cheng EY, Dykes DC, Thompson RC Jr. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. *J Orthop Res* 2000; 18:1-9.
2. Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, Wilcox GL. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. *J Neurosci* 2001; 21:9355-9366.
3. Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ, Wilcox GL. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. *Pain*. 2003; 101:175-186.
4. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Fink MP, Ramnaraine ML, Clohisy DR, Mantyh PW. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. *J Neurosci* 1999; 19:10886-10897.
5. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, O'Reilly T, Wotherspoon G, Winter J, Green J, Urban L. A rat model of bone cancer pain. *Pain* 2002; 96:129-140.
6. Clohisy DR, Ogilvie CM, Carpenter RJ, Ramnaraine ML. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. *J Orthop Res* 1996; 14:2-6.
7. Clohisy DR, Ogilvie CM, Ramnaraine ML. Tumor osteolysis in osteopetrotic mice. *J Orthop Res* 1995; 13:892-897.
8. Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, Lacey DL. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. *J Orthop Res* 2000; 18:967-976.
9. Sabino MA, Ghilardi JR, Jongen JL, Kevser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, Mantyh PW. Simultaneous reduction in cancer pain,

- bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. *Cancer Res* 2002; 62:7343-7349.
10. Honore P, Menning PM, Rogers SD, Nichols ML, Mantyh PW. Neurochemical plasticity in persistent inflammatory pain. *Prog Brain Res* 2000;129:357-363.
 11. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998; 93:165-176.
 12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]. *Cell* 1997; 89:309-319.
 13. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord [In Process Citation]. *Nat Med* 2000; 6:521-528.
 14. Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW. Osteoprotegerin diminishes advanced bone cancer pain. *Cancer Res* 2001; 61:4038-4047.
 15. Goblirsch M, Mathews W, Lynch C, Alaei P, Gerbi BJ, Mantyh PW, Clohisy DR. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. *Radiat Res* 2004; 161:228-234.
 16. Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, McNair K, Kesingland A, Green J, Chan O, Fox AJ, Urban LA. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. *Pain* 2002; 100:219-229.